Analysts expect Minerva Neurosciences Inc (NASDAQ:NERV) to post earnings per share of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Minerva Neurosciences’ earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.49). Minerva Neurosciences reported earnings per share of ($0.34) during the same quarter last year, which would indicate a negative year over year growth rate of 20.6%. The company is expected to announce its next earnings report on Tuesday, March 10th.
According to Zacks, analysts expect that Minerva Neurosciences will report full-year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($1.44). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.69) per share, with EPS estimates ranging from ($3.32) to ($0.91). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Minerva Neurosciences.
Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01.
A number of brokerages have recently issued reports on NERV. BidaskClub raised shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, August 23rd. Chardan Capital reaffirmed a “buy” rating on shares of Minerva Neurosciences in a research report on Monday, December 2nd. William Blair assumed coverage on shares of Minerva Neurosciences in a research note on Wednesday, September 18th. They issued an “outperform” rating and a $26.00 price objective for the company. Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. Finally, ValuEngine lowered shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Minerva Neurosciences has a consensus rating of “Buy” and a consensus target price of $17.44.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Minerva Neurosciences during the 3rd quarter valued at $35,000. Public Employees Retirement System of Ohio bought a new position in shares of Minerva Neurosciences in the second quarter worth $54,000. Parametric Portfolio Associates LLC bought a new position in shares of Minerva Neurosciences in the second quarter worth $56,000. Quantitative Systematic Strategies LLC bought a new position in shares of Minerva Neurosciences in the second quarter worth $62,000. Finally, Jane Street Group LLC acquired a new position in Minerva Neurosciences in the second quarter valued at about $88,000. 78.94% of the stock is owned by hedge funds and other institutional investors.
Shares of NERV traded up $0.11 during midday trading on Friday, reaching $6.25. 289,495 shares of the stock were exchanged, compared to its average volume of 313,383. Minerva Neurosciences has a twelve month low of $4.01 and a twelve month high of $8.83. The company has a market cap of $239.62 million, a P/E ratio of -4.84 and a beta of 1.59. The stock’s 50 day simple moving average is $5.16 and its 200 day simple moving average is $5.97.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Recommended Story: Producer Price Index (PPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.